Sebum: a window into dysregulation of lipid metabolism in Parkinson’s disease

Abstract

A metabolomics profiling approach was conducted to identify diagnostic biomarkers of PD from sebum, a non-invasively available biofluid. In this study, we used liquid chromatography-mass spectrometry (LC-MS) to analyse 274 samples from participants (80 drug naïve PD, 138 medicated PD and 56 well matched control subjects) and detected metabolites that could predict PD phenotype. Partial least squares-discriminant analysis (PLS-DA) models based on this sebum metabolome had correct classification rates of 70.4% and 69.7% to distinguish between drug naïve PD and medicated PD from control, respectively. Variable importance in projection (VIP) scores indicate compounds with significance belonged to sphingolipid, triacylglycerol and fatty acid/ester lipid classes. Pathway enrichment analysis showed alterations in lipid metabolism and mitochondrial dysfunction viz. the carnitine shuttle, sphingolipid metabolism and arachidonic acid metabolism. This study unveiled novel diagnostic sebum-based biomarkers for PD, and provides insight towards our current understanding of the pathogenesis of PD.

Content

Supplementary material

E.Sinclair LMS Sebum Parkinsons disease Supplementary Information
Clean ReSubmission E.Sinclair LCMS
Clean ReSubmission LCMS Supplementary Information